GLP-1RA vs SGLT-2i

Benefits

Comparisons

Evidence quality

Highlighted claims

• Estimated one-year weight change was -4.02 kg for GLP-1RA and -3.04 kg for SGLT-2i. — Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation
• The per-protocol difference was -0.98 kg, favoring GLP-1RA over SGLT-2i. — Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation
• In the FIRE target trial emulation, both GLP-1RA and SGLT-2i arms showed monotonic one-year weight loss. — Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation
• The estimated GLP-1RA versus SGLT-2i weight difference was close to SUSTAIN 8's semaglutide versus canagliflozin difference. — Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation
• GLP-1 receptor agonists and SGLT-2 inhibitors have randomized-trial evidence for cardiometabolic benefits in type 2 diabetes. — Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation
• Existing randomized trials are costly, selective, and usually evaluate specific agents rather than full drug classes in routine practice. — Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation
• The real-world result extends evidence from specific trial agents to full GLP-1RA and SGLT-2i classes in routine Swiss primary care. — Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation